FDA Licenses Merck’s Capvaxive Pneumococcal Vaccine
On June 17, 2024, the U.S. Food and Drug Administration (FDA) licensed Merck & Company, Inc.’s new pneumococcal conjugate vaccine Capvaxive (formerly V116) for adults 18 years of age and older. The vaccine is designed to protect against 21 types of the bacteria causing pneumococcal disease, which can lead to severe infection in the lungs […]
Global Pediatric Vaccines Market to Exceed $69 Billion by 2030
A report released by Coherent Market Insights showed that pediatric vaccines market will surpass $69.482 billion by 2030.1 The main pharmaceutical companies in the global market for pediatric vaccines include Bharat Biotech, Emergent BioSolutions, GSK, Indian Immunologicals, Merck, Panacea Biotec, Pfizer, Sanofi, Serum Institute and Zydus Cadila.2 Pediatric Vaccine Approvals by Governments Will Drive Vaccine […]